Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) COGS-to-Revenue : 0.03 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Eiger BioPharmaceuticals COGS-to-Revenue?

Eiger BioPharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.10 Mil. Its Revenue for the three months ended in Dec. 2023 was $3.80 Mil.

Eiger BioPharmaceuticals's COGS to Revenue for the three months ended in Dec. 2023 was 0.03.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Eiger BioPharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 was 97.34%.

Eiger BioPharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Eiger BioPharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eiger BioPharmaceuticals COGS-to-Revenue Chart

Eiger BioPharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.06

0.14

Eiger BioPharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.13	0.03	-0.07	0.04	0.03

Eiger BioPharmaceuticals COGS-to-Revenue Calculation

Eiger BioPharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.023999999999999	/	15.773
	=	0.00

Eiger BioPharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.101	/	3.803
	=	0.03

Eiger BioPharmaceuticals (OTCPK:EIGRQ) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Eiger BioPharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.101 / 3.803
	=	97.34 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Eiger BioPharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Eiger BioPharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eiger BioPharmaceuticals Inc (OTCPK:EIGRQ) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

72C:Germany 72C:Germany

Address

2155 Park Boulevard, Palo Alto, CA, USA, 94306

Website

https://www.eigerbio.com

Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Executives

Richard A Kayne	10 percent owner
Leen Kawas	10 percent owner	4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Ingrid Choong	officer: Chief Business Officer	24645 SUMMERHILL AVE, LOS ALTOS CA 94024
William G Kachioff	officer: CFO	4060 PORTE DE PALMAS, SAN DIEGO CA 92122
James Vollins	officer: General Counsel	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mayer Eldon C. Iii	officer: Ex VP & Chief Commerc. Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Lisa Kelly-croswell	director	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Thomas John Dietz	director	C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Jeffrey S Glenn	director	350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306
David Apelian	director	C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511
Sriram Ryali	officer: Chief Financial Officer	C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Christine Murray	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Erik Atkisson	officer: GC & Chief Compliance Officer	C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Kim Sablich	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
David A Cory	director, officer: President and CEO	350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306